What Polimerbio does

Polimerbio is a Spanish biotechnology company founded in 2017 as a spin-off from the ZIBIO Group (Science and Engineering of Polymeric Biomaterials) at the University of the Basque Country (UPV/EHU), integrated with POLYMAT since 2012. Headquartered at the Tandem building of the San Sebastián Technological Park (Paseo Miramón 170), the company specializes in the synthesis, characterization, and application of biodegradable polymers for biomedical use. Its core technology encompasses in-house polymer synthesis, HPLC-GPC analysis, and chemical synthesis capabilities supported by a laboratory equipped with fume hoods, chromatographic systems, and a jacketed reactor with capacity up to 3 kg. The firm develops both finished medical devices — most notably the DIB (Dispositivo Intracavitario Biodegradable), a Class III biodegradable urological stent for urethral stricture that eliminates the need for a second removal operation, and absorbable scaffolds for spinal cord regeneration — and a catalogue of chemical synthesis products including biodegradable polymers (BP series), functionalized polymers (FN series), monomers and initiators (IM series), dendrimers (DD series), polymeric meshes, and fullerenes (FL series).

The company's business model is dual-track. The medical device division targets healthcare institutions and medical specialists through direct B2B engagement, with commercialization contingent on completing clinical trials under ISO 13485:2016 quality management and EU MDR 2017/745 regulatory frameworks. The chemical synthesis division generates revenue through catalogue product sales and custom synthesis services delivered to academic research groups, pharmaceutical companies, and biotech firms requiring specialty polymers, dendrimers, fullerenes, and monomers for applications in drug delivery, tissue engineering, sensors, and photovoltaics. Polimerbio is currently in the preclinical-to-clinical transition phase, working toward first commercialization of its lead urological device while operating a smaller, ongoing catalogue and custom synthesis business.

Polimerbio's growth has been substantially grant-funded rather than venture-backed. Funding sources include a 2021 participative loan from Fundación Biozientziak Gipuzkoa Fundazioa, the multi-year AcroBioPLAST project (€1,503,666 total cost, €977,380.80 EU FEDER contribution via Interreg VI-A POCTEFA, 2024–2026), ENISA support, HAZITEK funding from the Basque Government, a 2020 round led by Clave Capital, and a 2025 round involving CDTI Innovación's INNVIERTE program, Kutxa Fundazioa, and Orza. Leadership transitioned in April 2022 when Pablo Fernández Echeverría was appointed CEO, succeeding founding CEO Juan Carlos Antigüedad.

Name

Polimerbio

Legal name

POLIMERBIO, S.L.

Website

https://polimerbio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Polimerbio is a San Sebastián-based biotech spin-off from the University of the Basque Country that develops biodegradable polymer-based medical devices (including a Class III urological stent) and supplies specialty chemical synthesis products to research institutions and biotech firms.

Ownership category

akta.pro rank

Product category

Biodegradable Medical Devices and Polymeric Biomaterials

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252), Medical Equipment and Supplies Manufacturing (3391)

SIC

Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

akta.pro secondary industries

Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT) (IMAEAOAA), Bio-based & Biodegradable Polymer Resin Manufacturing (PLA, PHA, PBS, starch blends) (IMANAAAG), Compostable & Bio-based Flexible Films and Sheet (extrusion/cast/blown) (IMANANAC)

Keywords

• Biodegradable polymers
• Medical devices
• Urological implants
• Chemical synthesis
• Tissue engineering

Headquarters

HQ city

San Sebastian

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Medical Devices Sales: Sale of proprietary medical devices based on biodegradable polymers, including the biodegradable urological stent for urethral stricture (DIB product) and scaffolds for spinal cord regeneration. The company was working toward commercialization by late 2023/early 2024.
2. Chemical Synthesis Products: Sale of chemical synthesis products including biodegradable polymers, functionalized polymers, monomers, initiators, dendrimers, polymeric meshes, and fullerenes. Products are offered via catalogue and custom synthesis services.
3. Custom Synthesis Services: Custom chemical synthesis solutions tailored to specific customer needs, working with team of experts at every stage of the process. Services include design and development of new synthetic routes.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Polimerbio designs, develops and manufactures biodegradable polymer-based medical devices and supplies advanced polymeric biomaterials through chemical synthesis. Its lead medical device is a Class III biodegradable urological stent (DIB) for urethral stricture, alongside absorbable scaffolds for spinal cord regeneration. The company also sells a catalog of biodegradable polymers, functionalized polymers, monomers, initiators, dendrimers, polymeric meshes, fullerenes and offers custom synthesis services.

Product overview

Polimerbio is a biotech company specializing in biodegradable polymer-based medical devices and chemical synthesis services. The company operates two main divisions: Medical Devices (including DIB urological implants and spinal cord regeneration scaffolds) and Chemical Synthesis (offering biodegradable polymers, functionalized polymers, monomers and initiators, dendrimers, polymeric meshes, and fullerenes). The product portfolio includes catalog products BP 001-012, FN 001-012, IM 001-007, DD 001-003, and FL 001-022, along with custom synthesis services for specialized chemical compounds.

Differentiator

Problem solved

Functional benefit

Products and services

• DIB (Dispositivo Intracavitario Biodegradable) Biodegradable Urological Stent A biodegradable urological tube indicated for urethral stricture designed to avoid a second removal operation, reduce hospitalization times and costs, and degrade as tissue regenerates and heals. Targeted at hospitals, urology departments, and medical specialists.
• Scaffolds for Spinal Cord Regeneration An absorbable device designed with the potential ability to promote attachment and guided cell movement to restore damaged spinal cord tissue so that patients can regain mobility. Targeted at spinal cord injury treatment centers and research institutions.
• Biodegradable Polymers (BP 001 - BP 012) Synthesis and development of biodegradable polymers including BP 001 (CAS: 24980-41-4, Mw: 90-200 KDa), BP 002 (CAS: 26023-30-3, Mw: 50-70 KDa), and BP 003-BP 012 (CAS: 70524-20-8) for biomedical engineering, 3D printing, inks, controlled drug release, and electrospinning. Targeted at research institutions and biotech companies.
• Functionalized Polymers (FN 001 - FN 012) Functionalized polymers (FN 001-012) with customizable molecular weights (0.8-16 kDa) and functionalization levels (10-100% alkyne/acrylate content) for advanced materials including sensors, responsive coatings, targeted drug delivery systems, and tissue engineering solutions. Targeted at academic and industrial R&D customers.
• Monomers and Initiators (IM 001 - IM 007) Innovative monomers and initiators (IM 001: CAS 3253-41-6, IM 002: CAS 248603-09-0, IM 003: CAS 2417844-44-9, IM 004: CAS 41514-88-9, IM 005: CAS 4986-89-4, IM 006: CAS 243991-62-0, IM 007) for tailored materials, responsive structures, controlled drug release, 3D printing, and biomedical engineering. Targeted at research institutions and biotech companies.
• Dendrimers (DD 001 - DD 003) Dendrimers with dendritic structure for drug delivery, diagnostics, and targeted therapies, including DD 001 (CAS: 1155417-73-4, Mw: 298.29 g/mol), DD 002 (CAS: 364320-55-8, Mw: 284.27 g/mol), and DD 003 (Mw: 1201.16 g/mol). Targeted at pharmaceutical and biomedical research customers.
• Polymeric Meshes Customizable polymeric meshes with randomly distributed or aligned fibers, customizable fiber diameter, and customizable mesh width for tissue engineering, filtration, and sensors applications. Targeted at research institutions and biotech companies.
• Fullerenes (FL 001 - FL 022) Fullerenes and derivatives including Mono & Bisadducts (FL 001-006), Hexakis-adducts (FL 013-017), Fullerene-C60 (CAS: 99685-96-8), ICMA (CAS: 186682-36-0), ICBA (CAS: 1207461-57-1), C60-PCBM (CAS: 160848-22-6), and C60-Bis-PCBM (CAS: 1048679-01-1) for applications in nanotechnology, organic photovoltaics, and biomedicine. Targeted at advanced materials and biomedical research customers.
• Custom Synthesis Services Custom chemical synthesis solutions tailored to specific customer needs, with the company's team of experts supporting design and development of new synthetic routes at every stage of the process. Targeted at research institutions, pharmaceutical companies, and biotech firms requiring specialized chemistry.

Quantifiable outcome

• Biodegradable urological stent reduces need for second operation and reduces hospitalization times and costs
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• UPV/EHU (Universidad del País Vasco / Euskal Herriko Unibertsitatea)coreStrategic or Co-development Partner · 1 January 2024Project leader in AcroBioPLAST consortium. Polimerbio collaborates with the university on research projects for biodegradable polymers and biomedical applications. The company originated as a spin-off from the ZIBIO Group (Science and Engineering of Polymeric Biomaterials Group) linked to the university, integrated with POLYMAT since 2012.
• UNIZAR (Universidad de Zaragoza)coreStrategic or Co-development Partner · 1 January 2024Partner institution in AcroBioPLAST project consortium focused on accelerating biodegradation of bioplastics and developing biomedical device prototypes.
• UPPA IPREM (Université de Pau et des Pays de l'Adour - Institut des Sciences Analytiques et de Physico-Chimie pour l'Environnement et les Matériaux)coreStrategic or Co-development Partner · 1 January 2024French partner in AcroBioPLAST consortium contributing expertise in analytical sciences and physico-chemical characterization of materials for environmental and materials applications.
• BIC Gipuzkoa (Bioincubadora)minorStrategic or Co-development Partner · 14 July 2022Polimerbio accesses common research facilities of the bioincubator in the Tandem building at San Sebastián Technological Park. Provides access to shared research infrastructure and ecosystem of biotech startups.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Polysciences Inc. Polysciences is a specialty manufacturer of polymers, monomers, and custom synthesis services for biomedical and research use, directly comparable to Polimerbio's chemical synthesis catalog (BP/FN/DD/IM/FL series) and custom synthesis services.
• Bezwada Biomedical: Bezwada Biomedical develops functional absorbable polymers and bioabsorbable medical devices, mirroring Polimerbio's focus on functionalized polymer chemistry (FN series) and Class III-style implantable medical devices.
• Reva Medical: Reva Medical develops bioresorbable polymer-based scaffolds (notably for vascular applications), directly comparable to Polimerbio's strategy of using proprietary polymer chemistry to build Class III implant devices that resorb after therapeutic effect.
• Bioretec Ltd. Bioretec is a Finnish medical device company developing bioresorbable orthopedic implants, directly comparable to Polimerbio's strategy of using biodegradable polymers to eliminate second-surgery removal in urological and other implant indications.
• Poly-Med Inc. Poly-Med is a US-based specialty manufacturer of bioresorbable polymers and absorbable medical devices, with a vertically integrated polymer-to-implant model closely paralleling Polimerbio's biodegradable polymer platform and DIB/scaffold approach.
• Tepha Inc. Tepha develops absorbable polymers (P4HB) for medical devices and tissue engineering, making it a direct comparable in the bioresorbable polymer and regenerative medicine space that Polimerbio targets with its BP polymer library and spinal cord scaffolds.

Broad incumbents

• Corbion: Corbion is a major producer of lactic acid-based bioplastics (including PLA) used in medical and pharmaceutical applications, making it both a comparable in biodegradable polymer manufacturing and a potential supply or partnership counterpart to Polimerbio.
• Evonik (Health Care segment): Evonik supplies bioresorbable polymers (e.g., RESOMER) for medical devices, drug delivery, and tissue engineering, positioning it as a broad incumbent peer in the same bio-based polymer space where Polimerbio competes with its BP and FN polymer families.
• DSM Biomedical (dsm-firmenich): DSM Biomedical is a large established supplier of biomedical-grade bioresorbable polymers and coatings used in medical devices, representing a broad incumbent competitor and potential partner/licensor for Polimerbio's polymer platform.

Emerging players

• Specific Polymers: Specific Polymers is a French SME that designs and custom-synthesizes functional polymers for healthcare and energy applications, closely mirroring Polimerbio's custom synthesis, functionalized polymer, and SME-scale biomedical polymer positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/polimerbio
• LinkedInes.linkedin.com/company/polimerbio

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polimerbio